Expiration date: 12/2025
The composition and form of issue:
1 capsule with pellets, enteric coated, contains lansoprazole 15 or 30 mg, in a contour acheikova packing 10 PCs., in box 3 packaging.
Pharmacological action:
Inhibits H+ — K+Atfazu (proton pump) of the parietal cells, blocks the final stage formation of hydrochloric acid, inhibits basal and stimulated secretion.
Pharmacokinetics:
Absorption is high. Cmax after oral administration at a dose of 30 mg achieved through 1, 5-2, 2 and h is 0, 75-1, 15 mg/l. Linking plasma protein — 98%. T1/2 — 1, 3-1, 7 h (increases with impaired renal function and in the elderly). Extensively metabolized in the primary passing through the liver. Excreted news in the form of metabolites (14-23%), and intestines.
Description pharmacological action:
Having a high lipophilicity easily penetrate cells parietalnae stomach, focuses them zitoproteguoe increases bicarbonate secretion. The inhibition of the formation of hydrochloric acid at the dose of 30 mg is 80-97%. Does not affect the motility of the gastrointestinal tract. Ingibiruty effect increases in the first four days of admission. Secretornaya activity restored in 3-4 days after drug withdrawal.
Indications:
Ulcers disease stomach and duodenal ulcers, reflux-ezofagit, erosivno-azwenne defeat stomach and duodenal ulcers in patients receiving NSAID or associated with Helicobacter pylori (composed of combination therapy), stress ulcer syndrome zollingerellison.
Contraindications:
Hypersensitivity, liver and/or kidney failure, pregnancy, breast-feeding, child age.
Application of pregnancy and breast-feeding:
Contraindicated. At the time of treatment should stop breastfeeding.
Side effects:
From the nervous system and sensory organs: headache, dizziness, drowsiness, in rare cases, depression.
From the digestive tract: diarrhea, abdominal pain, constipation.
Allergic reactions: skin rash.
From the respiratory system: rhinitis, pharyngitis.
Other: myalgia
Drug interactions:
Slows down the elimination of drugs, metaboliziruthan in the liver by mikrosomalnogo oxidation (including diazepam, fenitoina, indirect anticoagulants). Antatsida slow and reduce the absorption.
Method of application and dose:
Inside, in the morning before eating. Capsules should be swallowed whole, without chewing.
Peptic ulcer disease duodenal ulcer (in the acute stage): 30 mg/day for 2-4 weeks. (in resistant cases up to 60 mg/day).
Peptic ulcer (in the acute stage) and erosive ezofagit: 30-60 mg/day for 4-8 weeks.
Erosive-ulcerative lesions of the gastrointestinal tract in patients receiving NSAIDs: 30 mg/day for 4 -8 weeks.
Eradication of Helicobacter pylori: 30 mg 2 times a day for 10-14 days in combination with antibacterial agents.
Anti-relapse treatment of gastric ulcer and duodenal ulcer: 30 mg/day.
Relapse prevention treatment of reflux esophagitis: 30 mg/day for a long time (up to 6 months).
Syndrome zollingerellison: the dose selected individually to achieve the level of basal secretion is >10 mmol/h.
Precautions:
Before treatment to rule out a malignant process in the upper gastrointestinal tract.
